4.7 Review

Pathogenesis and Personalized Interventions for Pharmacological Treatment-Resistant Neuropsychiatric Symptoms in Alzheimer's Disease

Journal

JOURNAL OF PERSONALIZED MEDICINE
Volume 12, Issue 9, Pages -

Publisher

MDPI
DOI: 10.3390/jpm12091365

Keywords

Alzheimer's disease; neuropsychiatric symptoms (NPSs); treatment-resistant; antipsychotics; non-pharmacological symptom; the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer's Disease (CATIE-AD) trial

Ask authors/readers for more resources

Alzheimer's disease is the most common form of dementia, with cognitive impairment being the main symptom. Non-cognitive symptoms, known as neuropsychiatric symptoms (NPSs), also occur and worsen the prognosis. Current treatment guidelines recommend non-pharmacological treatments as the first line, followed by pharmacological treatments. However, pharmacological treatment for urgent NPSs can be challenging due to lack of efficacy or intolerance. Structural deterioration in elderly people with dementia and difficult psychosocial relations may contribute to this difficulty.
Alzheimer's disease (AD) is the most common form of dementia, with cognitive impairment as a core symptom. Neuropsychiatric symptoms (NPSs) also occur as non-cognitive symptoms during the disease course, worsening the prognosis. Recent treatment guidelines for NPSs have recommended non-pharmacological treatments as the first line of therapy, followed by pharmacological treatments. However, pharmacological treatment for urgent NPSs can be difficult because of a lack of efficacy or an intolerance, requiring multiple changes in psychotropic prescriptions. One biological factor that might be partly responsible for this difficulty is structural deterioration in elderly people with dementia, which may cause a functional vulnerability affecting the pharmacological response. Other causative factors might include awkward psychosocial interpersonal relations between patients and their caregiver, resulting in distressful vicious circles. Overlapping NPS sub-symptoms can also blur the prioritization of targeted symptoms. Furthermore, consistent neurocognitive reductions cause a primary apathy state and a secondary distorted ideation or perception of present objects, leading to reactions that cannot be treated pharmacologically. The present review defines treatment-resistant NPSs in AD; it may be necessary and helpful for clinicians to discuss the pathogenesis and comprehensive solutions based on three major hypothetical pathophysiological viewpoints: (1) biology, (2) psychosociology, and (3) neurocognition.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available